

1 **WO**

2

3

4

5 **IN THE UNITED STATES DISTRICT COURT**

6 **FOR THE DISTRICT OF ARIZONA**

7

8

9

10 IN RE: Bard IVC Filters Products Liability
11 Litigation,

12 _____

13 No. MDL 15-02641-PHX DGC

14 Debra and James Tinlin, a married couple,
15 Plaintiffs,

16 No. CV-16-00263-PHX-DGC

17 v.
18 C. R. Bard, Inc., a New Jersey corporation;
19 and Bard Peripheral Vascular, Inc., an
20 Arizona corporation,

21 Defendants.

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139

1140

1141

1142

1143

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253

1254

1255

1256

1257

1258

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329

1330

1331

1332

1333

1334

1335

1336

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

<

1 constitutes negligence that was a cause of Ms. Tinlin's injuries. Doc. 16578 at 1-2.
2 Plaintiffs contend that the evidence is irrelevant and unfairly prejudicial because
3 Dr. Riebe is not a defendant in the case and no medical malpractice claim is asserted
4 against him. *Id.* at 2-3.

5 Wisconsin law has "established without a doubt that, when apportioning
6 negligence, a jury must have the opportunity to consider the negligence of all parties to
7 the transaction, whether or not they be parties to the lawsuit and whether or not they can
8 be liable to the plaintiff or to the other tortfeasors." *Connar v. W. Shore Equip. of
9 Milwaukee, Inc.*, 227 N.W.2d 660, 662 (Wis. 1975); *see Heldt v. Nicholson Mfg. Co.*, 240
10 N.W.2d 154, 157 (Wis. 1976) (trial court did not err in including the plaintiff's employer
11 in the verdict where the record was replete with evidence of its negligence); *Hauboldt v.
12 Union Carbide Corp.*, 467 N.W.2d 508, 515 (Wis. 1991) ("We have held that in an action
13 for negligence, the jury must be given the opportunity to consider the possible negligence
14 of all persons, whether parties or not, who might have contributed to the total
15 negligence.") (citing *Connar*); *York v. Nat'l Cont'l Ins.*, 463 N.W.2d 364, 367 (Wis. Ct.
16 App. 1990) ("If there is evidence of conduct that, if believed by the jury, would constitute
17 negligence on the part of an actor, then that actor should be included in the special
18 verdict."). The fact that Dr. Riebe is not a party to this case and cannot be found liable
19 does not preclude Defendants from presenting evidence that he was negligent in selecting
20 a Recovery filter for Ms. Tinlin and that this was a cause of her injuries.

21 Ms. Tinlin's IVC size also is relevant to the failure to warn claims. The
22 Recovery's instructions for use ("IFU") cautioned that "[i]f the IVC diameter exceeds
23 28 mm, the filter must not be inserted into the IVC." Doc. 16893-1 at 2. Plaintiff claims
24 that Dr. Riebe would have read an IFU that contained an adequate warning and may have
25 changed his decision to use a Recovery for Ms. Tinlin. *See* Doc. 16893 at 4. Existing
26 warnings in the IFU clearly are relevant.

27 In his Tinlin report, Dr. Morris opines that a Recovery filter should not be placed
28 in an IVC larger than 28 mm because this can lead to tilt and migration. Doc. 15081-2

1 at 16-17, ¶ 1. He further opines that Dr. Riebe's decision to implant a Recovery in
2 Ms. Tinlin fell below the standard of care. *Id.* Based on Dr. Morris's recent deposition
3 testimony, Plaintiffs contend that he can only speculate that the IVC size and Dr. Riebe's
4 decision to implant a Recovery caused Ms. Tinlin's injuries. Doc. 16748 at 2-3.

5 Plaintiff has the burden of proof as to her claimed injuries, and her "medical
6 testimony in meeting such burden cannot be based on mere possibilities." *Hernke v. N.*
7 *Ins. Co. of N.Y.*, 122 N.W.2d 395, 399 (Wis. 1963). But in challenging Plaintiff's claim,
8 Defendants are "not required to confine [themselves] to reasonable medical
9 probabilities." *Id.* Rather, Defendants "may attempt to weaken the claim of injuries with
10 medical proof which is couched in terms of possibilities." *Id.*; see *Felde v. Kohnke*, 184
11 N.W.2d 433, 441 (Wis. 1971) ("It is clear that a contrary opinion to that presented by an
12 opposing party may be presented in terms of possibilities[.]"); *Roy v. St. Lukes Med. Ctr.*,
13 741 N.W.2d 256, 264 (Wis. Ct. App. 2007) (explaining that "a defense expert is allowed
14 to produce evidence of possibilities").

15 Plaintiff will claim that the filter's defective design caused her injuries, and
16 Defendants can respond with Dr. Morris's testimony that her injuries possibly were
17 caused by placement of the filter in an IVC that exceeded 28 mm. Plaintiffs will be free
18 to argue that this is a mere possibility and Dr. Morris's opinions are nothing more than
19 speculation and conjecture. *See id.* at 3-5. But the fact that Dr. Morris could not
20 "affirmatively state" the cause of Ms. Tinlin's injuries is no basis for excluding his
21 opinions under Wisconsin law. Doc. 16748 at 3; see *Hernke*, 122 N.W.2d at 399; *Roy*,
22 741 N.W.2d at 264. The motion in limine (Doc. 16578) is **denied**.¹

23
24 ¹ Defendants contend that the jury may apportion fault to Dr. Riebe based solely
25 on evidence that he breached the standard of care and therefore was negligent.
26 Docs. 16946 at 8-9, 16893 at 4. This is not correct. To apportion fault to physicians in
27 this case, Defendants must "prove that [they] were *causally* negligent." *Hegarty v.*
28 *Beauchaine*, 727 N.W.2d 857, 901 (Wis. Ct. App. 2006) (emphasis added). This requires
a showing not only of negligence, but also that the negligence was a substantial factor in
producing Ms. Tinlin's injuries. *See Fandrey v. Am. Family Mut. Ins.*, 680 N.W.2d 345,
353 (Wis. 2004); *Burton v. Am. Cyanamid*, No. 07-CV-0303, 2019 WL 325318, at *2
(E.D. Wis. Jan. 25, 2019); Wis JI-Civil 1023 (medical negligence standard); *see also*
Hegarty, 727 N.W.2d at 903 (rejecting the argument that the jury should have been
allowed to apportion fault to other physicians where the defendants failed to show that

1 **B. MIL 3 – Unrelated Medical Conditions.**

2 Plaintiffs seek to exclude evidence concerning certain medical conditions that they
3 claim are unrelated to the injuries caused by the Recovery filter:

4 • Graves' disease
5 • Surgical resection of the thyroid gland
6 • Hypothyroidism
7 • Sjogren's syndrome
8 • Hypertension
9 • Uterine and rectal prolapse
• Fibromyalgia and rheumatoid arthritis
• Pernicious anemia

10 Doc. 16577 at 1-2. Plaintiffs contend that these conditions are not relevant to any issue in
11 the case and would only mislead the jury, confuse the issues, and waste time. *Id.* at 3.

12 Defendants counter that the conditions carry symptoms that overlap with some of
13 Ms. Tinlin's claimed injuries – future cardiac complications, shortness of breath, back
14 pain, and a weakened trachea. Doc. 16938 at 3. Defendants cite various medical articles
15 purportedly showing the causal connections (*id.* at 2-5), but it is not clear that the
16 documents will be admissible at trial. Nor do Defendants identify any expert medical
17 testimony they will offer on the issue.

18 Under Wisconsin law, however, Defendants may cross-examine Plaintiffs' experts
19 as to whether it is possible that Ms. Tinlin's medical conditions are related to her claimed
20 injuries. *See Hernke*, 122 N.W.2d at 399. The Court cannot conclude that Ms. Tinlin's
21 medical conditions are irrelevant or otherwise inadmissible. The motion in limine
22 (Doc. 16577) is **denied**.²

23
24 “the alleged negligence *caused* [the patient's] injuries” (emphasis in original).

25 ² Defendants assert that the Recovery filter protected Ms. Tinlin when she needed
26 to stop anticoagulation treatment for various medical procedures between 2005 and 2015,
27 including procedures for uterine and rectal prolapse. Doc. 16938 at 3. Defendants agree
28 that they need not divulge the specific reasons that Ms. Tinlin temporarily stopped taking
anticoagulants as long as they can offer evidence that she needed to do so multiple times
over the years for conditions unrelated to this case. *Id.* at 3-4. The parties should confer
and agree on how evidence that Ms. Tinlin stopped anticoagulation from time to time will
be presented during trial.

C. MIL 4 – Rates of Filter Complications.

Plaintiffs anticipate that Defendants will attempt to use a chart they created from their internal TrackWise database regarding reporting rates of IVC filter complications. Doc. 16579 at 2. Plaintiffs contend that the chart is an untrustworthy hearsay document that fails the requirements of the business records exception provided by Rule 803(6). *Id.* at 2-3. Plaintiffs further contend that the chart is inadmissible under Rule 403 because any probative value it may have is substantially outweighed by the danger of unfair prejudice. *Id.* at 3-4.

Defendants assert that they have been fully candid in explaining what the internally calculated reporting rates represent, and Plaintiffs will be free to challenge the accuracy of the rates through evidence of their own and cross-examination of Defendants' witnesses. Doc. 16896 at 2-4. Defendants note that the chart was admitted in the Booker trial over Plaintiffs' hearsay and Rule 403 objections. *Id.* at 2; see Doc. 16896-1 at 13-16.

The Court will not predetermine whether Defendants will be able to lay adequate foundation for admission of the chart in the Tinlin trial, or whether the chart should be precluded under Rule 403. The motion in limine (Doc. 16579) is **denied**.³

D. MIL 5 – Retrievable Filter Sales Versus SNF Sales.

Plaintiffs seek to preclude Defendants from using a chart comparing the sales of the permanent Simon Nitinol filter (“SNF”) with those of retrievable filters between 2002 and 2016. Doc. 16580 at 1-2. Plaintiffs contend that the chart is not relevant because Ms. Tinlin received her filter in 2005. *Id.* at 2.

Plaintiffs will present evidence that the SNF is a reasonable alternative design to the Recovery filter. The Court concludes that Defendants should be allowed to present evidence of diminished SNF sales to show that the medical community viewed

³ Defendants were precluded in the Hyde trial from using reporting rates to claim that Bard filters are “99.9% effective.” See Doc. 16579-2. Defendants do not state that they will attempt to make the same claim in this case, but if they decide to do so, they should first raise the issue with the Court outside the presence of the jury.

1 retrievable filters – including the Recovery – as offering benefits over permanent-only
2 filters. The fact that the chart includes sales after Ms. Tinlin received her filter can be
3 pointed out to the jury and goes to the weight of the evidence, not its admissibility.
4 Plaintiffs have not shown that admission of the rates chart would mislead the jury or
5 result in unfair prejudice. The motion in limine (Doc. 16580) is **denied**.

6 **E. MIL 6 - Social Security Benefits.**

7 Plaintiffs contend that evidence regarding social security disability benefits Ms.
8 Tinlin applied for or received is barred by Wisconsin's collateral source rule. Doc. 16581
9 at 1-2. “[T]he collateral source rule states that benefits an injured person receives from
10 sources that have nothing to do with the tortfeasor may not be used to reduce the
11 tortfeasor's liability to the injured person.” *Leitinger v. DBart, Inc.*, 736 N.W.2d 1, 7
12 (Wis. 2007). The rule “generally precludes introduction of evidence regarding benefits a
13 plaintiff obtained from sources collateral to the tortfeasor.” *Id.* at 9.

14 Plaintiffs seek to exclude a June 8, 2005 letter Dr. Stanko wrote in support of
15 Ms. Tinlin's application for permanent disability, a phone message regarding a request
16 for the letter, and Dr. Stanko's deposition testimony about the letter. Doc. 16581 at 2; *see*
17 Doc. 16583. Defendants make clear, however, that they will not offer evidence of
18 Ms. Tinlin's disability to show that she received benefits from a collateral source as
19 compensation for her claimed injuries or to offset any potential damages award.
20 Doc. 16897 at 2. Indeed, Defendants acknowledge that “an award of damages cannot be
21 limited or reduced by a collateral source payment.” Doc. 16897 at 2. Defendants instead
22 intend to use the evidence to show that Ms. Tinlin's deep vein thrombosis with
23 pulmonary emboli was a serious condition and she was permanently disabled before her
24 Recovery filter failed. Doc. 16897 at 2-3.

25 Plaintiffs have not shown that the challenged evidence is inadmissible. The
26 motion in limine (Doc. 16581) is **denied**.

27 ///

28 ///

1 **II. Defendants' MILs.**

2 **A. MIL 1 – Recovery Death Evidence.**

3 In each of the other bellwether cases tried in this MDL – Booker, Jones, and
4 Hyde – Defendants have moved to exclude evidence of deaths caused by Recovery filter
5 cephalad migration. Docs. 9862, 10677, 10288. The Court denied the motion in the
6 Booker case, which concerned a G2 filter, finding that the evidence concerned the device
7 that was a predicate for the G2 in Defendants' FDA submissions and also would be
8 necessary for the jury to understand what prompted design changes in the G2.
9 Doc. 10323 at 4. The Court reached a different conclusion in the Jones and Hyde cases
10 because the G2 design eliminated cephalad migration, the cases concerned filters that
11 were two or three generations after the Recovery (G2X and Eclipse), the plaintiffs
12 received the filters more than four years after the Recovery was taken off the market, and
13 Recovery filter cephalad migration deaths – which stopped after the G2 was introduced –
14 said little if anything about the plaintiffs' claims regarding the G2X and Eclipse. The
15 Court concluded that Recovery death evidence had only marginal relevance that was
16 substantially outweighed by the danger of unfair prejudice. Docs. 10819 at 3-5, 12533
17 at 6-7; *see* Docs. 10920, 11041 (orders denying motion for reconsideration in Jones).

18 Defendants contend that the Court's reasoning in Booker should not apply in this
19 case because the Court did not consider whether cephalad migration was substantially
20 similar to complications Ms. Booker's G2 filter experienced. Doc. 16575 at 2. But this
21 case concerns the Recovery filter. Plaintiffs contend that the Recovery was defectively
22 designed, presented unusually high risks to patients, and continued to be marketed despite
23 Defendants' knowledge of high failure rates and deaths. Plaintiff Tinlin contends that she
24 never would have received a Recovery filter if Defendants' had disclosed these increased
25 risks to her doctor, and that Defendants' continued marketing of this dangerous product
26 warrants punitive damages. The Recovery deaths are directly relevant to these claims.

27 To establish the strict liability design defect claim, Plaintiffs must show that the
28 Recovery's "foreseeable risks of harm" could have been reduced by an alternative

1 reasonable design, and that omission of the alternative design rendered the Recovery
2 “not reasonably safe.” Wis. Stat. § 897.047(1)(a). Plaintiffs must also show that the
3 alleged defect rendered the Recovery “unreasonably dangerous[.]” § 895.047(b).
4 Recovery filter patient deaths and Defendants’ knowledge of those deaths go directly to
5 the Recovery’s foreseeable risks of harm and whether it was unreasonably dangerous.

6 Defendants contend that Plaintiff Tinlin did not experience the kind of whole-filter
7 cephalad migration that resulted in the reported deaths, but Plaintiffs contend that same
8 filter defects and instability that caused cephalad migration led to the kinds of migration,
9 tilting, perforation of the IVC, and fracturing that Ms. Tinlin experienced.

10 Recovery death evidence also is relevant to Plaintiffs’ failure to warn and
11 concealment claims. Ms. Tinlin’s implanting physician, Dr. Riebe, testified that he
12 needed complete and accurate information from medical device manufacturers to help
13 him conduct a proper risk-benefit analysis. Doc. 15702-1 at 5. He explained that a
14 manufacturer’s concealment of true risks prevents him from conducting such an analysis.
15 *Id.* He further stated that he would have wanted to know that Bard had placed the
16 Recovery on hold due to significant migration problems and internally found the
17 Recovery to have unacceptable risks. *Id.* at 6-8, 14. This information would have been
18 important to him in understanding the Recovery’s safety and conducting a proper risk-
19 benefit analysis. *Id.* at 8-9, 19. The fact that patients died from Recovery migration
20 problems is probative on the causation issue – that is, whether Dr. Riebe would have
21 selected a different filter for Ms. Tinlin had he been warned about the Recovery’s true
22 risks, as Plaintiffs describe them.

23 Defendants cite *Cooper v. Firestone Tire & Rubber Co.*, 945 F.2d 1103, 1105 (9th
24 Cir. 1991), for the proposition that a showing of substantial similarity is required when a
25 plaintiff attempts to introduce evidence of other incidents of product failure as direct
26 proof of negligence or defect. Doc. 16575 at 2. But substantial similarity is not required
27 when the other incidents are used to impeach an expert’s testimony that a product is safe.
28 See *Cooper*, 945 F.2d at 1105. Indeed, even where other-incident evidence may have

“some prejudicial effect, it [is] also highly probative of the credibility of the assertion of [defense] experts that the [product] was generally safe.” *Id.* Defendants clearly will assert in this case that the Recovery filter was safe and effective.

Defendants note that the Court expressed concern in Booker that too heavy an emphasis on deaths could result in unfair prejudice that substantially outweighs the probative value of the cephalad migration evidence. *Id.* at 3 (citing Doc. 10323 at 4). The Court has the same concern in this case, but this is no basis for precluding the evidence before trial. Defendants may object during trial if they believe Plaintiffs are overemphasizing the cephalad migration deaths.

Defendants contend that admitting the death evidence to support an award of punitive damages would violate due process and Wisconsin law. *Id.* at 4. To recover punitive damages, Plaintiffs must show that Defendants “acted maliciously” or in an “intentional disregard of the rights” of Plaintiffs. Wis. Stat. 895.043(3); *see Strenke v. Hogner*, 694 N.W.2d 296, 304-05 (Wis. 2005). The jury may consider Defendants’ “attitude and conduct” and “the degree of [Defendants’] awareness of the hazard and of its excessiveness.” Wis JI-Civil § 1707.2; *see Doc. 12438 at 38-39*. Evidence that Bard continued to market the Recovery in the face of unusually high patient deaths is relevant to Bard’s state of mind.⁴ Moreover, the death evidence “can help to show that the conduct that harmed [Ms. Tinlin] also posed a substantial risk of harm to the general public, and so was particularly reprehensible[.]” *Philip Morris USA v. Williams*, 549 U.S. 346, 355 (2007); *see State Farm Mut. Auto. Ins. v. Campbell*, 538 U.S. 408, 419 (2003) (explaining the “most important indicium of the reasonableness of a punitive damages award is the degree of reprehensibility of the defendant’s conduct,” which includes whether “the tortious conduct evinced an indifference to or a reckless disregard

⁴ The Court reached a different conclusion in Jones because cephalad migration deaths stopped when the Recovery was taken off the market in 2005, and the deaths shed little light on Defendants' state of mind when marketing different filters with different complications, years later. Doc. 10819 at 5.

1 of the health or safety of others") (quoting *BMW of N. Am., Inc. v. Gore*, 517 U.S. 559,
2 574 (1996)).

3 Defendants' reliance on *Henrikson* and *Kehl* is misplaced. Doc. 16575 at 4. Each
4 case involved a separate act of fleeing the scene of the accident that caused the plaintiff
5 no injury. *See Henrikson v. Strapon*, 758 N.W.2d 205, 215 (Wis. Ct. App. 2008)
6 ("[T]here is no evidence that Strapon's fleeing the scene caused an injury to Henrikson or
7 aggravated any injury he received from being hit by Strapon's car[.]"); *Kehl v. Econ. Fire*
8 & *Cas.*, 433 N.W.2d 279, 281 (Wis. Ct. App. 1988) ("The collision . . . resulted from
9 negligence and was distinct from the fleeing, which was a separate volitional act.").
10 Plaintiffs contend that the Recovery migration problems that caused Ms. Tinlin's injuries
11 and the deaths of other patients resulted from the same flawed design. Doc. 16943 at 2.

12 Defendants have not shown that Recovery death evidence is inadmissible in this
13 case. The motion in limine (Doc. 16575) is **denied**.

14 **B. MIL 2 – FDA Warning Letter.**

15 Defendants re-urge their motion to exclude the 2015 FDA warning letter.
16 Docs. 9864, 16572; *see* Doc. 9864-1; Ex. 1680. The Court previously found the that the
17 following topics in the letter lack probative value: Topics 1 and 2 (Recovery cone
18 retrieval system), topic 4(a) (filter cleaning process), and topics 4(b), 5, 6, 7 and 8 (Denali
19 filter). Doc. 10258 at 6-8; Booker Trial Tr. at 1890. Plaintiffs have not shown that topics
20 1, 2, 4 and 6 are relevant to any issue in this case. Plaintiffs contend that topics 7 and 8
21 show that Bard failed to properly report adverse events, and this evidence demonstrates a
22 pattern of concealment that is relevant to the failure to warn claims and punitive
23 damages. Doc. 16945 at 2. But the adverse events in topics 7 and 8 involved Bard's
24 latest-generation filter – the Denali – which is not at issue in this case. The Court will
25 **grant** the motion (Doc. 16572) with respect to topics 1-2 and 4-8.

26 Topic 3 concerns Bard's regulatory violations for failure to establish and maintain
27 procedures for receiving, evaluating, and reporting IVC filter complaints, and expressly
28 references the G2 and Eclipse – the filters at issue in the other bellwether trials.

1 Doc. 9864-1 at 5-6. The Court deferred ruling on the relevance of topic 3 until trial in
2 Booker, and took the same approach in Jones and Hyde. *See* Doc. 10805. The Court
3 ultimately concluded in Booker that topic 3 was relevant because much evidence had
4 been presented about the MAUDE database and adverse event reports to the FDA, the
5 data upon which Bard relied in making reports, and Bard's root cause analysis. Topic 3
6 was relevant to rebut the implication, if not the express argument, that the FDA never
7 took action against Bard. *See* Booker Trial Tr. at 1888-89. The Court noted that topic 3
8 included reference to the G2, the filter at issue in Booker. *Id.* at 1889. The Court reached
9 similar conclusions in Jones and Hyde. *See* Docs. 11256, 12736.

10 Defendants contend that topic 3 should be excluded in this case because it has
11 nothing to do with the Recovery filter and is not otherwise relevant to any issue or claim.
12 Doc. 16572 at 2-4. Defendants further contend that the presentation of evidence about
13 the warning letter would waste important trial time and only confuse the jury about the
14 true issues in the case. *Id.* at 4.

15 Plaintiffs counter that topic 3 is relevant for the same reasons it was relevant in the
16 other bellwether trials. Doc. 16945 at 2-4. Plaintiffs assert that although topic 3 does not
17 reference the Recovery by name, it covers Bard's processes for the entire IVC filter line,
18 including the Recovery. *Id.* at 3-4. Plaintiffs note that the Court previously rejected
19 Defendants' Rule 403 objections. *Id.* at 4.

20 The decision on this issue will need to be made at trial once the relevancy of
21 topic 3 can be determined in light of all the facts presented. Plaintiffs shall raise the issue
22 with the Court outside the presence of the jury before seeking to admit the FDA warning
23 letter. The motion (Doc. 16572) is **denied** in this regard.⁵

24 **C. MIL 3 – Crisis Communications Plan.**

25 Defendants seek to exclude the Recovery Filter Crisis Communications Plan
26 (“CCP”) that Bard had prepared in 2004 to help manage damaging media coverage about
27

28 ⁵ If topic 3 of the letter is deemed admissible at trial, Plaintiffs shall make appropriate redactions before offering it into evidence. *See* Booker Trial Tr. at 1889-90.

1 a Recovery migration death. Doc. 16573. Defendants contend that the CCP is irrelevant
2 for three reasons.

3 First, Plaintiffs cannot show a substantial similarity between the cephalad
4 migration death that prompted the CCP and Ms. Tinlin's filter failures and resulting
5 injuries. *Id.* at 2 (citing *Cooper*, 945 F.2d at 1105; *State Farm*, 538 U.S. at 422). But as
6 explained above, cephalad migration deaths are relevant to Plaintiffs' claims.

7 Second, the CCP was never put into action and therefore had no causal impact on
8 Plaintiffs' claims or injuries. *Id.* at 2-3. Defendants' causal connection is not the only
9 relevant issue in this case. The CCP is relevant to Defendants' understanding of the risks
10 presented by Recovery, their response to those risks, and, potentially, their state of mind
11 for punitive damages.

12 Third, the CCP does not support Plaintiffs' punitive damages claim because
13 retaining a public relations firm to help manage negative media coverage of product
14 failures is good corporate policy. *Id.* at 3. This may be a good jury argument, but it does
15 not render the CCP irrelevant. The CCP notes that, as a result of unfavorable press
16 coverage, "stock prices may plummet [and] analysts may downgrade the affected
17 company's rating[.]" Doc. 16573-1 at 3. The CCP goes to Bard's attitude toward
18 Recovery complications and is relevant to Plaintiffs' claim that Bard acted with
19 intentional disregard of Plaintiff's rights. *See* Wis. Stat. 895.043(3); Wis JI-Civil
20 § 1707.2. Defendants will be free to argue that the CCP was never finalized and contains
21 "template language" not specific to or approved by Bard (Doc. 16753 at 4), but this goes
22 to CCP's evidentiary weight, not its admissibility.

23 The Court cannot conclude that the CCP is irrelevant. Nor does the Court find it
24 inadmissible under Rule 403. The motion in limine (Doc. 16573) is **denied**.


25 **D. MIL 4 – Patient at Dr. Muehrcke's Hospital.**

26 Dr. Muehrcke was a consulting physician for a patient who had a Bard filter and
27 purportedly died from cardiac tamponade. He recently opined in a state-court deposition
28 that the patient's cardiac tamponade was caused by a fractured strut that had embolized to

1 her heart. Doc. 16574-1 at 8. Defendants seek to preclude Plaintiffs from referencing
2 this opinion during opening statements or eliciting it during Dr. Muehrcke's direct
3 examination because it is not included in Dr. Muehrcke's expert reports and was not
4 offered during his deposition in this case. Doc. 16574 at 2-3 & n.2.

5 As the Court outlined in Case Management Order No. 8, expert reports under
6 Rule 26(a)(2)(B) must set forth "the testimony the witness is expected to present during
7 direct examination, together with the reasons therefor." Doc. 519 at 3, ¶ 6 (citation
8 omitted). Plaintiffs note that Dr. Muehrcke opines in his Tinlin report that "pulmonary
9 fragments are known to cause . . . death" and "an additional strut can embolize at any
10 time to [Ms. Tinlin's] heart causing her to suffer cardiac tamponade[.]" Doc. 16951 at 2.
11 But this says nothing about his opinion in the state-court case that one of his patients died
12 from cardiac tamponade caused by a fractured strut. Plaintiffs have not timely disclosed
13 that opinion in this case, nor have they shown that the failure to disclose is substantially
14 justified or harmless. Plaintiffs therefore are precluded from eliciting the opinion during
15 opening statements and direct examination of Dr. Muehrcke. *See Fed. R. Civ. P. 37(c)(1)*
16 (a party that fails to disclose information required by Rule 26(a) "is not allowed to use
17 that information . . . at a trial, unless the failure was substantially justified or harmless");
18 *see also Yeti by Molly Ltd. v. Deckers Outdoor Corp.*, 259 F.3d 1101, 1106 (9th Cir.
19 2001) ("Rule 37(c)(1) gives teeth to these requirements by forbidding the use at trial of
20 any information required to be disclosed by Rule 26(a) that is not properly disclosed.").
21 The motion in limine (Doc. 16574) is **granted**.⁶

22 Dated this 26th day of April, 2019.

23
24
25 
26

27
28 David G. Campbell
Senior United States District Judge

⁶ Given this ruling, the Court need not address whether the opinion should be excluded under Rules 403 and 702. *See* Doc. 16574 at 3-4.